Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8115 of 9079 results

  1. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    In development Reference number: GID-TA10960 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    Discontinued Reference number: GID-TA10606

    Technology appraisal guidance
    Discontinued

  3. Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

    In development Reference number: GID-TA11863 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    Discontinued Reference number: GID-TA11128

    Technology appraisal guidance
    Discontinued

  5. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]

    In development Reference number: GID-TA11481 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]

    In development Reference number: GID-TA11808 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  9. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  10. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  11. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

    Technology appraisal guidance
    Discontinued

  12. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    Discontinued Reference number: GID-TA10822

    Technology appraisal guidance
    Discontinued

  13. Insulin icodec for treating type 2 diabetes [ID6175]

    In development Reference number: GID-TA11104 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  15. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

    NICE guideline
    Discontinued